Cristina Tănăseanu *, Şt. Tănăseanu **
* Dr. Tănăseanu Cristina, şef de lucrări Spitalul „Sf. Pantelimon”, Clinica medicală, UMF „Carol Davila” Bucureşti
** Dr. Tănăseanu Ştefăniţă, şef de lucrări Spitalul „N. Gh. Lupu”, Clinica medicală, UMF „Carol Davila”, Bucureşti
Abstract
Deep venous thrombosis, pulmonary embolism and arterial thrombosis represent a group of serious diseases with lethal potential. Low molecular weight heparines (LMWH) play an important role among different therapeutic modalities by their anticoagulant effect, easy use in patients, low rate of secondary effects and safety in ambulatory patients. LMWH are the therapy of choice in patients with high thrombotic risk.